These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer. Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500 [TBL] [Abstract][Full Text] [Related]
6. Stomach-Specific Activation of Oncogenic KRAS and STAT3-Dependent Inflammation Cooperatively Promote Gastric Tumorigenesis in a Preclinical Model. Thiem S; Eissmann MF; Elzer J; Jonas A; Putoczki TL; Poh A; Nguyen P; Preaudet A; Flanagan D; Vincan E; Waring P; Buchert M; Jarnicki A; Ernst M Cancer Res; 2016 Apr; 76(8):2277-87. PubMed ID: 26837764 [TBL] [Abstract][Full Text] [Related]
7. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS. Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346 [TBL] [Abstract][Full Text] [Related]
8. IL-6/STAT3 axis initiated CAFs via up-regulating TIMP-1 which was attenuated by acetylation of STAT3 induced by PCAF in HCC microenvironment. Zheng X; Xu M; Yao B; Wang C; Jia Y; Liu Q Cell Signal; 2016 Sep; 28(9):1314-1324. PubMed ID: 27297362 [TBL] [Abstract][Full Text] [Related]
9. Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice. Ye H; Zhang C; Wang BJ; Tan XH; Zhang WP; Teng Y; Yang X Oncogene; 2014 Oct; 33(43):5133-8. PubMed ID: 24213574 [TBL] [Abstract][Full Text] [Related]
10. YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling. Gruber R; Panayiotou R; Nye E; Spencer-Dene B; Stamp G; Behrens A Gastroenterology; 2016 Sep; 151(3):526-39. PubMed ID: 27215660 [TBL] [Abstract][Full Text] [Related]
11. Expression of connective tissue growth factor in the livers of non-viral hepatocellular carcinoma patients with metabolic risk factors. Akahoshi K; Tanaka S; Mogushi K; Shimada S; Matsumura S; Akiyama Y; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Tanabe M J Gastroenterol; 2016 Sep; 51(9):910-22. PubMed ID: 26739296 [TBL] [Abstract][Full Text] [Related]
12. Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma. Zhuang PY; Wang JD; Tang ZH; Zhou XP; Quan ZW; Liu YB; Shen J BMC Cancer; 2015 Nov; 15():830. PubMed ID: 26525581 [TBL] [Abstract][Full Text] [Related]
13. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562 [TBL] [Abstract][Full Text] [Related]
14. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling. Wang Y; Ma H; Zhao C; Liu T; Yan D; Jou D; Li H; Zhang C; Lü J; Li C; Lin J; Li S; Lin L Oncotarget; 2017 May; 8(20):33683-33693. PubMed ID: 28430601 [TBL] [Abstract][Full Text] [Related]
15. Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling. Luo YD; Liu XY; Fang L; Yu HQ; Zhang YJ; Chen M; Zhang LD; Xie CM Theranostics; 2022; 12(18):7903-7919. PubMed ID: 36451866 [No Abstract] [Full Text] [Related]
16. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer. Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150 [TBL] [Abstract][Full Text] [Related]
17. Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. Won C; Kim BH; Yi EH; Choi KJ; Kim EK; Jeong JM; Lee JH; Jang JJ; Yoon JH; Jeong WI; Park IC; Kim TW; Bae SS; Factor VM; Ma S; Thorgeirsson SS; Lee YH; Ye SK Hepatology; 2015 Oct; 62(4):1160-73. PubMed ID: 26154152 [TBL] [Abstract][Full Text] [Related]
18. Molecular dissection of gp130-dependent pathways in hepatocytes during liver regeneration. Dierssen U; Beraza N; Lutz HH; Liedtke C; Ernst M; Wasmuth HE; Trautwein C J Biol Chem; 2008 Apr; 283(15):9886-95. PubMed ID: 18216023 [TBL] [Abstract][Full Text] [Related]
19. IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma. Yin Z; Ma T; Lin Y; Lu X; Zhang C; Chen S; Jian Z J Cell Biochem; 2018 Nov; 119(11):9419-9432. PubMed ID: 30015355 [TBL] [Abstract][Full Text] [Related]
20. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Gu FM; Li QL; Gao Q; Jiang JH; Zhu K; Huang XY; Pan JF; Yan J; Hu JH; Wang Z; Dai Z; Fan J; Zhou J Mol Cancer; 2011 Dec; 10():150. PubMed ID: 22171994 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]